Inhibikase provides pipeline updates after sharp stock decline; 201 Trial enrollment at 28 patients

Inhibikase Therapeutics, Inc.

Stock dropped dramatically over last 8 trading sessions; no identifiable cause for volatility.
Risvodetinib 201 Trial: 28 of 120 patients enrolled/screening; one completed 12-week dosing; portal added 50 potential participants in Sept.
Safety data for risvodetinib presented on 119 people at MDS Congress; no side effects of clinical significance.
IkT-001Pro: FDA meeting request steps completed; bioequivalence study to 600 mg imatinib mesylate due early Q4 2023.
Cash position sufficient to fund operations into Q4 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.